Literature DB >> 26655423

Ibrutinib in chronic lymphocytic leukaemia: alone or in combination?

Tadeusz Robak1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26655423     DOI： 10.1016/S1470-2045(15)00519-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.

Authors:  Preetesh Jain; Michael J Keating; William G Wierda; Mariela Sivina; Philip A Thompson; Alessandra Ferrajoli; Zeev Estrov; Hagop Kantarjian; Susan O'Brien; Jan A Burger
Journal:  Clin Cancer Res       Date:  2016-10-19       Impact factor: 12.531

Review 2.  Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

3.  Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.

Authors:  Ian W Flinn; John G Gribben; Martin J S Dyer; William Wierda; Michael B Maris; Richard R Furman; Peter Hillmen; Kerry A Rogers; Swaminathan Padmanabhan Iyer; Anne Quillet-Mary; Loic Ysebaert; Harriet S Walter; Maria Verdugo; Christian Klein; Huang Huang; Yanwen Jiang; Gerard Lozanski; Daniela Soriano Pignataro; Kathryn Humphrey; Mehrdad Mobasher; Thomas J Kipps
Journal:  Blood       Date:  2019-03-12       Impact factor: 22.113
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.